Drugs / NNC6019-0001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06260709 | Feb 2024 → Feb 2028 expected | amyloidosis | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05442047 | Aug 2022 → Feb 2025 | amyloidosis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07207811 | Oct 2025 → Jun 2029 expected | amyloidosis | Novo Nordisk A/S | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-27 | Prothena Biosciences Ltd. | Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy prothena.com ↗ |
| 2026-03-09 | Prothena Biosciences Ltd. | Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy prothena.com ↗ |
| 2025-11-11 | Prothena Biosciences Ltd. | Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA prothena.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC6019-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05442047 ↗ |
| Known as | coramitug | “CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid...” NCT07207811 ↗1“Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis.” PMID 41212997 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “Coramitug is a humanized monoclonal antibody” PMID 41212997 ↗ Nov 2025 |
| Route | Intravenous | “administered intravenously every 28 days” PMID 39472768 ↗ Oct 2024 |
| Target | TTR | “BACKGROUND: Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current...” PMID 41212997 ↗ Nov 2025 |